Exact Mass: 511.1286
Exact Mass Matches: 511.1286
Found 136 metabolites which its exact mass value is equals to given mass value 511.1286
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
3-Methyl-1-hydroxybutyl-ThPP
3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. [HMDB] 3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4].
2-Methyl-1-hydroxybutyl-ThPP
2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted from (S)-3-Methyl-2-oxopentanoic acid via the enzyme 2-oxoisovalerate dehydrogenase E1 component, alpha subunit(EC 1.2.4.4). It is then converted to S-(2-Methylbutanoyl)-dihydrolipoamide-E via the same enzyme. 2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted
trans-zeatin riboside diphosphate
A purine ribonucleoside 5-diphosphate that is ADP substituted at position N-6 by a (2E)-4-hydroxy-3-methylbut-2-en-1-yl group.
Uzel (TN)
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D020011 - Protective Agents > D000931 - Antidotes C2140 - Adjuvant > C2078 - Folic Acid Derivative D018977 - Micronutrients > D014815 - Vitamins Therapeutic category: 3929 Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer[1][2].
Cefetamet pivoxyl
4-[2-[(1R)-1-(N-(4-Chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid
2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid
Hygromycin A
Cys Cys Met Arg
Cys Cys Arg Met
Cys Cys Thr Trp
Cys Cys Trp Thr
Cys Asp Phe Gln
Cys Asp Gln Phe
Cys Glu Phe Asn
Cys Glu Asn Phe
Cys Phe Asp Gln
Cys Phe Glu Asn
Cys Phe Asn Glu
Cys Phe Gln Asp
Cys Met Cys Arg
Cys Met Met Gln
Cys Met Gln Met
Cys Met Arg Cys
Cys Asn Glu Phe
Cys Asn Phe Glu
Cys Gln Asp Phe
Cys Gln Phe Asp
Cys Gln Met Met
Cys Arg Cys Met
Cys Arg Met Cys
Cys Thr Cys Trp
Cys Thr Trp Cys
Cys Trp Cys Thr
Cys Trp Thr Cys
Asp Cys Phe Gln
Asp Cys Gln Phe
Asp Phe Cys Gln
Asp Phe Gln Cys
Asp Gln Cys Phe
Asp Gln Phe Cys
Glu Cys Phe Asn
Glu Cys Asn Phe
Glu Phe Cys Asn
Glu Phe Asn Cys
Glu Asn Cys Phe
Glu Asn Phe Cys
Phe Cys Asp Gln
Phe Cys Glu Asn
Phe Cys Asn Glu
Phe Cys Gln Asp
Phe Asp Cys Gln
Phe Asp Gln Cys
Phe Glu Cys Asn
Phe Glu Asn Cys
Phe Asn Cys Glu
Phe Asn Glu Cys
Phe Gln Cys Asp
Phe Gln Asp Cys
Met Cys Cys Arg
Met Cys Met Gln
Met Cys Gln Met
Met Cys Arg Cys
Met Met Cys Gln
Met Met Gln Cys
Met Gln Cys Met
Met Gln Met Cys
Met Arg Cys Cys
Asn Cys Glu Phe
Asn Cys Phe Glu
Asn Glu Cys Phe
Asn Glu Phe Cys
Asn Phe Cys Glu
Asn Phe Glu Cys
Gln Cys Asp Phe
Gln Cys Phe Asp
Gln Cys Met Met
Gln Asp Cys Phe
Gln Asp Phe Cys
Gln Phe Cys Asp
Gln Phe Asp Cys
Gln Met Cys Met
Gln Met Met Cys
Arg Cys Cys Met
Arg Cys Met Cys
Arg Met Cys Cys
Thr Cys Cys Trp
Thr Cys Trp Cys
Thr Trp Cys Cys
Trp Cys Cys Thr
Trp Cys Thr Cys
Trp Thr Cys Cys
sodium 3-[[4-(benzoylethylamino)-2-methylphenyl]azo]-4-hydroxynaphthalene-1-sulphonate
Arzoxifene hydrochloride
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Leucovorin Calcium
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D020011 - Protective Agents > D000931 - Antidotes C2140 - Adjuvant > C2078 - Folic Acid Derivative D018977 - Micronutrients > D014815 - Vitamins Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer[1][2].
BMS 299897
[6-acetyloxy-5-(2,5-dioxopyrrol-1-yl)-3-oxospiro[2-benzofuran-1,9-xanthene]-3-yl] acetate
Cefetamet Pivoxil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
(2-Amino-2-biphenylyl)(chloro)palladium - tris(2-methyl-2-propanyl)phosphine (1:1)
(E)-CefetametPivoxil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
7,10,13-Tri(carboxymethyl)-5,15-dioxo-4,7,10,13,16-pentaaza-1,19-dithianonadecane
(E)-N-[(3aS,4R,5S,6S,7R,7aR)-4,6,7-trihydroxy-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-5-yl]-3-[4-[(2S,3S,4S,5S)-5-acetyl-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyphenyl]-2-methylprop-2-enamide
(E)-3-[4-(5-acetyl-3,4-dihydroxyoxolan-2-yl)oxy-3-hydroxyphenyl]-2-methyl-N-(4,6,7-trihydroxy-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-5-yl)prop-2-enamide
[3,4-dihydroxy-5-[6-[[(E)-4-hydroxy-3-methylbut-2-enyl]amino]purin-9-yl]oxolan-2-yl]methyl phosphono hydrogen phosphate
2-[(3-cyano-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)thio]-N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]acetamide
2,4-Dichloro-benzoic acid 2-{[4-(2,2-dimethyl-propionylamino)-benzoyl]-hydrazonomethyl}-phenyl ester
N-[3-[[[3-[(5-bromo-2-pyridinyl)-[(4-chlorophenyl)methyl]amino]propylamino]-sulfanylidenemethyl]amino]propyl]acetamide
CVT-11127
CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1]. CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].
PPTN (hydrochloride)
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity[1].